Approach to lower the cardiovascular risk of individuals with Type 2 Diabetes Mellitus: Evidence-based consensus statements of the Philippine Heart Association and Philippine Society of Endocrinology Diabetes and Metabolism
- Author:
Jorge A. Sison
1
;
Cecilia A. Jimeno
2
;
Bien J. Matawaran
3
;
Imelda Caole-Ang
4
;
Eddieson M. Gonzales
5
Author Information
- Publication Type:Journal Article
- Keywords: Treatment recommendations
- MeSH: Diabetes Mellitus, Type 2; Heart Disease Risk Factors
- From: Philippine Journal of Internal Medicine 2021;59(2):67-83
- CountryPhilippines
- Language:English
- Abstract: Diabetes remains as the 6th leading cause of death in the Philippines, with more than 33,000 deaths in 2016. Given this alarming prevalence, it is imperative that this public health concern be prioritized in the country and to answer such concern, a group of cardiologists and endocrinologists who are in active clinical practice and research, formed a technical working group composed of five members. Their primary objective was to develop an evidence-based consensus document for Filipino healthcare practitioners and people in the academe that would serve as a guideline on the approach to lower the CV risk of individuals with T2DM. The TWG agreed on focusing with the pharmacological approach to treatment of lowering CV risk for T2DM patients using the ADAPTE model which is a more systematic approach to guideline adaptation. The recommendations were developed using the ADAPTE framework appraising all international practice guidelines and recommendations through to 2013. The technical working group’s overall objective of guideline adaptation is to take advantage of the existing guidelines to enhance the efficient production and use of high-quality adapted guidelines specially in the local Philippine setting. Each of these articles was then assessed using the AGREE instrument. Based on the key questions that the technical working group had identified regarding the approach to lower the risk of individuals with type 2 diabetes, 9 recommendations concerning the antidiabetic drug of choice for persons with type 2 diabetes with or without established ASCVD and management of type 2 diabetes mellitus patients with hypertension and dyslipidemia were drafted and are presented in this report.
- Full text:1 PHA.pdf
